$ARIA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARIAD PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARIAD PHARMACEUTICALS INC. Get notifications about new insider transactions in ARIAD PHARMACEUTICALS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Option Exercise | D | 23.82 | 25,000 | 595,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Option Exercise | D | 4.91 | 25,000 | 122,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Option Exercise | D | 6.45 | 25,000 | 161,250 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Option Exercise | D | 7.39 | 25,000 | 184,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Option Exercise | D | 20.98 | 40,000 | 839,200 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Sell | D | 0.00 | 55,508 | 0 | 0 | 55.5 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Gift | G | 0.00 | 15,600 | 0 | 0 | 15.6 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | D | 0.00 | 14,550 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | D | 0.00 | 72,980 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | D | 6.51 | 87,125 | 567,184 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | D | 20.89 | 65,000 | 1,357,850 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | D | 15.05 | 82,000 | 1,234,100 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | D | 0.00 | 577 | 0 | 0 | 577 to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | D | 0.00 | 219,867 | 0 | 0 | 219.9 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Haimovitz Jules | Director | Option Exercise | D | 23.82 | 25,000 | 595,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Haimovitz Jules | Director | Option Exercise | D | 6.65 | 75,000 | 498,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Haimovitz Jules | Director | Sell | D | 0.00 | 18,008 | 0 | 0 | 18 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bickerstaff George | Director | Option Exercise | D | 23.82 | 25,000 | 595,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bickerstaff George | Director | Option Exercise | D | 6.65 | 75,000 | 498,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bickerstaff George | Director | Sell | D | 0.00 | 18,008 | 0 | 0 | 18 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Herron Jennifer Lyn | Exec V.P. Chief Com ... | Option Exercise | D | 0.00 | 5,291 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Herron Jennifer Lyn | Exec V.P. Chief Com ... | Option Exercise | D | 8.85 | 300,000 | 2,655,000 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Herron Jennifer Lyn | Exec V.P. Chief Com ... | Sell | D | 0.00 | 450 | 0 | 0 | 450 to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 0.00 | 9,788 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 0.00 | 64,733 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 6.51 | 78,000 | 507,780 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 6.40 | 100,000 | 640,000 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Sell | D | 0.00 | 42,834 | 0 | 0 | 42.8 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Gansler Jayne M. | Senior V.P. Human R ... | Option Exercise | D | 0.00 | 2,910 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Gansler Jayne M. | Senior V.P. Human R ... | Option Exercise | D | 0.00 | 72,000 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Gansler Jayne M. | Senior V.P. Human R ... | Option Exercise | D | 8.86 | 144,000 | 1,275,840 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Option Exercise | D | 23.82 | 25,000 | 595,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Option Exercise | D | 4.91 | 25,000 | 122,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Option Exercise | D | 6.45 | 25,000 | 161,250 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Option Exercise | D | 7.39 | 25,000 | 184,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Option Exercise | D | 8.50 | 25,000 | 212,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Sell | D | 0.00 | 139,867 | 0 | 0 | 139.9 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | D | 0.00 | 3,439 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | D | 0.00 | 52,666 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | D | 6.51 | 60,000 | 390,600 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | D | 20.89 | 48,000 | 1,002,720 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | D | 15.05 | 38,000 | 571,900 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Sell | D | 0.00 | 126,352 | 0 | 0 | 126.4 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Option Exercise | D | 0.00 | 66,800 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Option Exercise | D | 5.34 | 1,500,000 | 8,010,000 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Sell | D | 0.00 | 159,378 | 0 | 0 | 159.4 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Option Exercise | D | 23.82 | 25,000 | 595,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Option Exercise | D | 4.91 | 25,000 | 122,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Option Exercise | D | 8.87 | 75,000 | 665,250 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Sell | D | 0.00 | 41,910 | 0 | 0 | 41.9 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Soni Manmeet Singh | EVP, CFO & Treasure ... | Option Exercise | D | 0.00 | 7,937 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Soni Manmeet Singh | EVP, CFO & Treasure ... | Option Exercise | D | 6.47 | 550,000 | 3,558,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Soni Manmeet Singh | EVP, CFO & Treasure ... | Sell | D | 0.00 | 3,273 | 0 | 0 | 3.3 K to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Kogan Elona Esq. | Sr. V. P. - General ... | Option Exercise | D | 0.00 | 6,085 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Kogan Elona Esq. | Sr. V. P. - General ... | Option Exercise | D | 0.00 | 100,000 | 0 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Kogan Elona Esq. | Sr. V. P. - General ... | Option Exercise | D | 7.13 | 200,000 | 1,426,000 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | D | 9.30 | 3,459,280 | 32,176,493 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | D | 9.30 | 5,340,720 | 49,676,707 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | D | 23.82 | 25,000 | 595,500 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | D | 4.91 | 25,000 | 122,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | D | 6.45 | 25,000 | 161,250 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | D | 8.73 | 75,000 | 654,750 | 0 | |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Sell | D | 0.00 | 5,051,335 | 0 | 0 | 5.1 M to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Sell | D | 0.00 | 7,798,665 | 0 | 0 | 7.8 M to 0 (-100.00 %) |
| Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Sell | D | 0.00 | 53,173 | 0 | 0 | 53.2 K to 0 (-100.00 %) |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 9,788 | 0 | 9,788 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 12,500 | 0 | 0 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 6,667 | 0 | 6,667 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Payment of Exercise | F | 8.69 | 6,249 | 54,304 | 42,834 | 49.1 K to 42.8 K (-12.73 %) |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 6,667 | 0 | 49,083 | 42.4 K to 49.1 K (+15.72 %) |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 12,500 | 0 | 42,416 | 29.9 K to 42.4 K (+41.78 %) |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Kogan Elona Esq. | Sr. V. P. - General ... | Option Exercise | A | 0.00 | 6,085 | 0 | 6,085 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Soni Manmeet Singh | EVP, CFO & Treasure ... | Option Exercise | A | 0.00 | 7,937 | 0 | 7,937 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | A | 0.00 | 3,439 | 0 | 3,439 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | A | 0.00 | 14,550 | 0 | 14,550 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Gansler Jayne M. | Senior V.P. Human R ... | Option Exercise | A | 0.00 | 2,910 | 0 | 2,910 | |
| Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Herron Jennifer Lyn | Exec V.P. Chief Com ... | Option Exercise | A | 0.00 | 5,291 | 0 | 5,291 | |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | M | 0.00 | 29,333 | 0 | 0 | |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Payment of Exercise | F | 23.81 | 14,667 | 349,293 | 126,352 | 141 K to 126.4 K (-10.40 %) |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Buy | M | 0.00 | 29,333 | 0 | 141,019 | 111.7 K to 141 K (+26.26 %) |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | M | 0.00 | 29,333 | 0 | 0 | |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Payment of Exercise | F | 23.82 | 9,610 | 228,886 | 219,867 | 229.5 K to 219.9 K (-4.19 %) |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Buy | M | 0.00 | 29,333 | 0 | 229,477 | 200.1 K to 229.5 K (+14.66 %) |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Option Exercise | A | 23.82 | 25,000 | 595,500 | 25,000 | |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Grant | A | 0.00 | 12,500 | 0 | 53,173 | 40.7 K to 53.2 K (+30.73 %) |
| Feb 02 2017 | ARIA | ARIAD PHARMACEUTIC ... | DENNER ALEXANDER J | Director | Grant | A | 0.00 | 5,508 | 0 | 40,673 | 35.2 K to 40.7 K (+15.66 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bickerstaff George | Director | Option Exercise | A | 23.82 | 25,000 | 595,500 | 25,000 | |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bickerstaff George | Director | Grant | A | 0.00 | 12,500 | 0 | 18,008 | 5.5 K to 18 K (+226.94 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bickerstaff George | Director | Grant | A | 0.00 | 5,508 | 0 | 5,508 | 0 to 5.5 K |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Option Exercise | A | 23.82 | 25,000 | 595,500 | 25,000 | |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Grant | A | 0.00 | 12,500 | 0 | 55,508 | 43 K to 55.5 K (+29.06 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Schlesinger Sarah J. | Director | Grant | A | 0.00 | 5,508 | 0 | 43,008 | 37.5 K to 43 K (+14.69 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Haimovitz Jules | Director | Option Exercise | A | 23.82 | 25,000 | 595,500 | 25,000 | |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Haimovitz Jules | Director | Grant | A | 0.00 | 12,500 | 0 | 18,008 | 5.5 K to 18 K (+226.94 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Haimovitz Jules | Director | Grant | A | 0.00 | 5,508 | 0 | 5,508 | 0 to 5.5 K |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Option Exercise | A | 23.82 | 25,000 | 595,500 | 25,000 | |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Grant | A | 0.00 | 12,500 | 0 | 139,867 | 127.4 K to 139.9 K (+9.81 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | RIEDEL NORBERT G | Director | Grant | A | 0.00 | 5,508 | 0 | 127,367 | 121.9 K to 127.4 K (+4.52 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Option Exercise | A | 23.82 | 25,000 | 595,500 | 25,000 | |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Grant | A | 0.00 | 12,500 | 0 | 41,910 | 29.4 K to 41.9 K (+42.50 %) |
| Feb 01 2017 | ARIA | ARIAD PHARMACEUTIC ... | Protopapas Anna | Director | Grant | A | 0.00 | 5,508 | 0 | 29,410 | 23.9 K to 29.4 K (+23.04 %) |
| Jan 17 2017 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Option Exercise | M | 0.00 | 66,600 | 0 | 66,800 | |
| Jan 17 2017 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Payment of Exercise | F | 23.69 | 33,300 | 788,934 | 159,378 | 192.7 K to 159.4 K (-17.28 %) |
| Jan 17 2017 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Buy | M | 0.00 | 66,600 | 0 | 192,678 | 126.1 K to 192.7 K (+52.82 %) |
| Jan 10 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | M | 7.82 | 32,000 | 250,240 | 0 | |
| Jan 10 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Sell | S | 23.78 | 32,000 | 760,960 | 129,404 | 161.4 K to 129.4 K (-19.83 %) |
| Jan 10 2017 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Buy | M | 7.82 | 32,000 | 250,240 | 161,404 | 129.4 K to 161.4 K (+24.73 %) |
| Oct 25 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 9.56 | 19,638 | 187,739 | 197,884 | 217.5 K to 197.9 K (-9.03 %) |
| Oct 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Sell | S | 13.46 | 47,384 | 637,812 | 129,404 | 176.8 K to 129.4 K (-26.80 %) |
| Sep 28 2016 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
| Sep 28 2016 | ARIA | ARIAD PHARMACEUTIC ... | Bollag Daniel M | Sr. VP, Reg. Affair ... | Buy | M | 0.00 | 10,000 | 0 | 176,788 | 166.8 K to 176.8 K (+6.00 %) |
| Sep 28 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | M | 0.00 | 17,500 | 0 | 0 | |
| Sep 28 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 13.98 | 8,750 | 122,311 | 217,522 | 226.3 K to 217.5 K (-3.87 %) |
| Sep 28 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Buy | M | 0.00 | 17,500 | 0 | 226,272 | 208.8 K to 226.3 K (+8.38 %) |
| Sep 23 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 13.43 | 20,000 | 268,536 | 208,772 | 228.8 K to 208.8 K (-8.74 %) |
| Sep 16 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | M | 7.82 | 59,369 | 464,266 | 0 | |
| Sep 16 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 11.73 | 59,369 | 696,398 | 228,772 | 288.1 K to 228.8 K (-20.60 %) |
| Sep 16 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Buy | M | 7.82 | 59,369 | 464,266 | 288,141 | 228.8 K to 288.1 K (+25.95 %) |
| Aug 23 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 10.47 | 19,436 | 203,538 | 228,772 | 248.2 K to 228.8 K (-7.83 %) |
| Aug 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | M | 7.69 | 25,000 | 192,250 | 0 | |
| Aug 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 10.50 | 25,000 | 262,500 | 248,208 | 273.2 K to 248.2 K (-9.15 %) |
| Aug 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Buy | M | 7.69 | 25,000 | 192,250 | 273,208 | 248.2 K to 273.2 K (+10.07 %) |
| Jul 25 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 8.11 | 18,286 | 148,230 | 248,208 | 266.5 K to 248.2 K (-6.86 %) |
| Jul 25 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 8.11 | 18,286 | 148,230 | 248,208 | 266.5 K to 248.2 K (-6.86 %) |
| Jul 19 2016 | ARIA | ARIAD PHARMACEUTIC ... | Kogan Elona Esq. | Sr. V. P. - General ... | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Jul 19 2016 | ARIA | ARIAD PHARMACEUTIC ... | Kogan Elona Esq. | Sr. V. P. - General ... | Option Exercise | A | 7.13 | 200,000 | 1,426,000 | 200,000 | |
| Jul 14 2016 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Option Exercise | M | 0.00 | 66,600 | 0 | 133,400 | |
| Jul 14 2016 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Payment of Exercise | F | 7.14 | 28,611 | 204,283 | 126,078 | 154.7 K to 126.1 K (-18.50 %) |
| Jul 14 2016 | ARIA | ARIAD PHARMACEUTIC ... | Panayiotopoulos Paris | President and CEO | Buy | M | 0.00 | 66,600 | 0 | 154,689 | 88.1 K to 154.7 K (+75.61 %) |
| Jul 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | M | 3.25 | 30,000 | 97,500 | 0 | |
| Jul 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Option Exercise | M | 4.49 | 31,422 | 141,085 | 0 | |
| Jul 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 7.48 | 30,000 | 224,481 | 266,494 | 296.5 K to 266.5 K (-10.12 %) |
| Jul 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Buy | M | 3.25 | 30,000 | 97,500 | 296,494 | 266.5 K to 296.5 K (+11.26 %) |
| Jul 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 7.48 | 31,422 | 235,153 | 266,494 | 297.9 K to 266.5 K (-10.55 %) |
| Jul 05 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Buy | M | 4.49 | 31,422 | 141,085 | 297,916 | 266.5 K to 297.9 K (+11.79 %) |
| Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 6,666 | 0 | 6,667 | |
| Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 12,500 | 0 | 0 | |
| Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Sell | S | 7.05 | 6,012 | 42,385 | 29,916 | 35.9 K to 29.9 K (-16.73 %) |
| Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 6,666 | 0 | 35,928 | 29.3 K to 35.9 K (+22.78 %) |
| Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 12,500 | 0 | 29,262 | 16.8 K to 29.3 K (+74.57 %) |
| Jun 23 2016 | ARIA | ARIAD PHARMACEUTIC ... | CLACKSON TIMOTHY P | President, R&D, CSO | Sell | S | 7.28 | 23,999 | 174,638 | 264,742 | 288.7 K to 264.7 K (-8.31 %) |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Option Exercise | M | 4.91 | 6,250 | 30,688 | 18,750 | |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Option Exercise | M | 6.45 | 25,000 | 161,250 | 0 | |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Option Exercise | M | 7.39 | 15,000 | 110,850 | 0 | |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Option Exercise | M | 7.39 | 10,000 | 73,900 | 15,000 | |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Option Exercise | M | 5.49 | 10,000 | 54,900 | 0 | |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Option Exercise | M | 5.49 | 10,000 | 54,900 | 10,000 | |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Sell | S | 8.24 | 46,250 | 381,137 | 131,631 | 177.9 K to 131.6 K (-26.00 %) |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Buy | M | 4.91 | 6,250 | 30,688 | 177,881 | 171.6 K to 177.9 K (+3.64 %) |
| Jun 15 2016 | ARIA | ARIAD PHARMACEUTIC ... | LAVIDAS ATHANESE | Director | Buy | M | 6.45 | 25,000 | 161,250 | 171,631 | 146.6 K to 171.6 K (+17.05 %) |